NOVEL FOOD and PARNUTS approval granted for NKO(R) opens the 2nd largest nutraceutical market for Neptune



    LAVAL, QC, Feb. 19 /CNW Telbec/ - Neptune Technologies & Bioressources
Inc. ("Neptune") (NASDAQ.NEPT - TSX.V.NTB) is pleased to announce today that
the European Food Safety Association (EFSA) has approved Neptune Krill Oil
(NKO(R)) as a NOVEL FOOD and PARNUTS for commercialization in the European
Union.
    NKO(R) has successfully passed rigorous regulatory review and scrutiny by
all member states of the European Union (EU), which approved NKO(R) as a NOVEL
FOOD and PARNUTS allowing its immediate commercialization at a clinically
proven effective daily dose in all 27 European countries.

    
    - NOVEL FOOD opens the European market to NKO(R) for:
      - Dietary Supplements
      - Functional Foods

    - PARNUTS approval allows the commercialization of NKO(R) as:
      - Diet Meal Replacements
      - Dietary Foods for Special Medical Purposes
    

    "NKO(R)'s strong clinically proven benefits for cardiovascular health
will now lead Neptune's further expansion in the European omega-3 market,
which is currently dominated by cardiovascular health applications with 80% of
all omega-3 fatty acids targeting heart benefits," stated Dr. Toni Rinow,
Corporate Development and Investor Relations of Neptune. "According to market
studies, the EU market is growing annually by 24 % and is expected to be worth
$1.6 billion by 2014(1)," she added.
    "According to EFSA regulations, functional food and dietary supplements
can only be commercialized at the daily dose established as safe, which is not
always necessarily the effective dose. Fortunately, the daily dose accepted by
EFSA as safe for NKO(R) is also the one proven to be effective in all clinical
studies with NKO(R)," stated Dr. Tina Sampalis, Chief Scientific Officer of
Neptune. "This opens the door for NKO(R) to gain a leadership position in both
dietary supplements and functional food markets, achieving targets unmet by
other omega-3 products and krill competition," she added.
    "Moreover, the NKO(R) PARNUTS approval, which allows the
commercialization of NKO(R) for the dietary management of specific diseases,
is expected to lead Neptune and its subsidiaries to major pharmaceutical
opportunities," she concluded.
    Neptune has already built substantial marketing visibility and
recognition in Europe through its longstanding annual presence at Vitafoods
International, the Global Nutraceutical Event, in Geneva, Switzerland, and
Health and Food Ingredients in Paris, France. Based on these continuing
marketing efforts, the proprietary status of its ingredients and the Novel
Food approval, Neptune expects to accelerate market penetration and increase
its market share of the omega-3 health ingredient market.

    (1) Frost & Sullivan's European Analysis 2008

    About Neptune Technologies & Bioressources Inc.

    Neptune researches and develops proprietary bioactive ingredients and
products for nutraceutical and pharmaceutical applications and is carrying out
clinical research to show the therapeutic benefits of its products in various
medical indications. The Company patents and protects its innovations and is
continuously expanding its intellectual property portfolio. Neptune has
already obtained many regulatory approvals allowing commercialization of its
products in various geographic markets and has filed for and is expecting
additional approvals. The Company expects to launch its first functional food
product in early 2009 with its partners Marine Life Science and Weider Global
Nutrition.

    NASDAQ does not accept responsibility for the adequacy or accuracy of
    this press release. Neither TSX Venture Exchange nor its Regulation
    Services Provider (as that term is defined in the policies of the TSX
    Venture Exchange) accepts responsibility for the adequacy or accuracy of
    this release.

    Statements in this press release that are not statements of historical or
current fact, including statments relating to the Company's expectation
regarding the future performance and marketability of its products, constitute
"forward-looking statements" within the meaning of the U.S. Private Securities
Litigation Reform Act of 1995 and Canadian securities laws. Such
forward-looking statements involve known and unknown risks, uncertainties, and
other unknown factors that could cause the actual results of the Company to be
materially different from historical results or from any future results
expressed or implied by such forward-looking statements. In addition to
statements which explicitly describe such risks and uncertainties, readers are
urged to consider statements labeled with the terms "believes," "belief,"
"expects," "intends," "anticipates,"should," "will," or "plans" to be
uncertain and forward-looking. The forward-looking statements contained herein
are also subject generally to other risks and uncertainties that are described
from time to time in the Company's reports filed with the Securities and
Exchange Commission and the Canadian securities commissions.




For further information:

For further information: Toni Rinow, Ph.D., MBA Corporate Development &
Investor Relations, Neptune Technologies & Bioressources Inc., (450) 687-2262,
t.rinow@neptunebiotech.com; www.neptunebiotech.com; Source: Neptune
Technologies & Bioressources Inc.

Organization Profile

Neptune Technologies and Bioressources Inc.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890